Business Context and Reporting Period
Company: Recursion Pharmaceuticals, Inc. (RXRX)
Filing Type: Form 10-Q (Unaudited)
Period Ended: September 30, 2025
Business Overview: Recursion is a clinical-stage TechBio company utilizing the Recursion Operating System (OS) to industrialize drug discovery through AI and wet-lab integration. The company operates as a single segment and has not yet commercialized any products. As of September 30, 2025, the company held an accumulated deficit of approximately $2.0 billion.
Key Financial Metrics
| Metric (in thousands) | Q3 2025 | Q3 2024 | 9M 2025 | 9M 2024 |
|---|---|---|---|---|
| Total Revenue | $5,175 | $26,082 | $39,143 | $54,293 |
| Net Loss | $(162,253) | $(95,842) | $(536,637) | $(284,755) |
| Net Loss Per Share (Basic/Diluted) | $(0.36) | $(0.34) | $(1.27) | $(1.12) |
| Operating Cash Flow | N/A | N/A | $(325,735) | $(243,744) |
| Cash and Cash Equivalents (End of Period) | $659,836 | N/A | $659,836 | N/A |
| Total Debt (Notes & Leases) | $20,821 | N/A | $20,821 | N/A |
Note: Q3 Operating Cash Flow is not explicitly broken out in the provided text; only the 9-month figure is available.
Material Changes vs. Prior Period
- Revenue Decline: Total revenue decreased 80% in Q3 2025 compared to Q3 2024 ($5.2M vs. $26.1M) and 28% for the nine-month period. The Q3 decline is attributed to the timing of revenue recognition from strategic alliances (Sanofi, Roche, Merck) and the absence of a specific milestone acceptance fee recognized in the prior year.
- Expense Increase: Operating expenses rose 43% in Q3 and 66% for the nine months ended September 30, 2025.
- R&D Expenses: Increased 62% in Q3 and 76% for the nine months. Drivers include the inclusion of Exscientia operations, acquired in-process research and development (IPR&D) charges of $22.8M, and Tempus data purchases.
- Cost of Revenue: Increased 22% in Q3 and 75% for the nine months, primarily due to the integration of Exscientia customers.
- Acquisitions and Disposals:
- Completed the acquisition of Exscientia plc (Nov 2024), which is now consolidated in results.
- Acquired 100% of RE Ventures I (Rallybio interest) in July 2025 for $20.2M, expensed as IPR&D.
- Sold Austrian operations (Exscientia GmbH) in March 2025, recording a $4.5M loss on disposal.
- Financing Activity: The company raised significant capital through equity issuances. In the nine months ended Sept 30, 2025, net proceeds from common stock issuances totaled $395.5M. A subsequent event in October 2025 saw the completion of the Citi ATM offering, raising an additional $133.5M.
Guidance, Outlook, and Risks
- Liquidity Outlook: Management believes existing cash and cash equivalents ($659.8M as of Sept 30, 2025) are sufficient to fund operations for at least the next 12 months. However, the company expects to incur substantial operating losses in the future and will require additional capital to advance drug candidates.
- Pipeline Catalysts:
- REC-617 (CDK7): Phase 1/2 ELUCIDATE trial established MTD at 10mg; expanded into platinum-resistant ovarian cancer.
- REC-7735 (PI3Kα): Nominated as a Development Candidate; IND-enabling studies underway.
- Milestones: The company expects over $100M in milestone payments by the end of 2026. A $30M milestone from Roche was triggered in October 2025 (subsequent event) for the acceptance of a second neuroscience Phenomap.
- Internal Controls: The company disclosed that disclosure controls and procedures were ineffective as of September 30, 2025, due to material weaknesses related to revenue recognition cost models and the integration of Exscientia's financial controls. Remediation efforts are ongoing but not yet complete.
- Risk Factors: Key risks include the uncertainty of clinical trial outcomes, the need for additional financing, potential limitations on tax net operating losses (Section 382), and ongoing legal proceedings (including a dismissed securities class action against Exscientia with leave to re-file).
Investor Verification Checklist
- Cash Burn Rate: Verify the sustainability of the $659.8M cash balance against the $536.6M net loss for the nine-month period and projected R&D spend.
- Revenue Recognition: Review the specific timing and constraints applied to variable consideration (milestones) from major partners (Roche, Sanofi, Merck) given the significant volatility in quarterly revenue.
- Internal Control Remediation: Monitor progress on remediating the material weaknesses in internal controls over financial reporting, specifically regarding revenue recognition and Exscientia integration.
- Acquisition Integration: Assess the financial impact and synergy realization of the Exscientia acquisition, including the $22.8M IPR&D charge and ongoing operational costs.
- Legal Contingencies: Track the status of the re-filed securities class action regarding Exscientia and the ongoing lease dispute with Industry Office SLC, LLC.